Abstract
Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of proteinaceous material within the lungs. While typically managed with whole lung lavage (WLL), more recent PAP therapies aimed at reducing granulocyte–macrophage colony stimulating factor autoantibodies (anti-GM-CSF) have reduced symptoms and improved lung function. We present a patient with PAP refractory to WLL, exogenous GM-CSF and rituximab who underwent a novel plasmapheresis protocol as a therapeutic trial. While previously reported regimens have utilized plasmapheresis sessions distributed over months, our patient underwent five consecutive days of plasmapheresis, followed by rituximab. Anti-GM-CSF levels decreased from 24.8 to 2.7 mcg/mL post-plasmapheresis. This reduction of autoantibody correlated with reduction in WLL frequency, increase in diffusing capacity for carbon monoxide, and subjective improvement in dyspnea. Our case suggests that five consecutive days of plasmapharesis results in increased clearance of anti-GM-CSF and may be potentially efficacious in cases of refractory PAP.
This is a preview of subscription content, log in via an institution to check access.
Abbreviations
- CT:
-
Computed tomography
- DLCO:
-
Diffusing capacity for carbon monoxide
- GM-CSF:
-
Granulocyte–macrophage colony stimulating factor
- IgG:
-
Immunoglobulin-G
- PAP:
-
Pulmonary alveolar proteinosis
- TLC:
-
Total lung capacity
- WLL:
-
Whole lung lavage
References
Rosen SH, Castleman B, Liebow AA (1958) Pulmonary alveolar proteinosis. N Engl J Med 258(23):1123–1142
Seymour JF, Presneill JJ (2002) Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 166(2):215–235
Trapnell BC, Whitsett JA, Nakata K (2003) Pulmonary alveolar proteinosis. N Engl J Med 349(26):2527–2539
Beccaria M, Luisetti M, Rodi G et al (2004) Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J 23(4):526–531
Kavuru MS, Sullivan EJ, Piccin R et al (2000) Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 161(4 Pt 1):1143–1148
Abdul Rahman JA, Moodley YP, Phillips MJ (2004) Pulmonary alveolar proteinosis associated with psoriasis and complicated by mycobacterial infection: successful treatment with granulocyte-macrophage colony stimulating factor after a partial response to whole lung lavage. Respirology 9(3):419–422
Kavuru MS, Malur A, Marshall I et al (2011) An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J 38(6):1361–1367
Bonfield TL, Kavuru MS, Thomassen MJ (2002) Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 105(3):342–350
Luisetti M, Rodi G, Perotti C et al (2009) Plasmapheresis for treatment of pulmonary alveolar proteinosis. Eur Respir J 33(5):1220–1222
Sakagami T, Uchida K, Suzuki T et al (2009) Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med 361(27):2679–2681
Keller AJ, Urbaniak SJ (1978) Intensive plasma exchange on the cell separator: effects on serum immunoglobulins and complement components. Br J Haematol 38(4):531–540
Acknowledgments
The authors thank Dr. Bruce Trapnell, Division of Pulmonary Biology, Cincinnati Children’s Medical Center for running the anti-GM-CSF levels.
Conflict of interest
The authors have reported to Lung that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Garber, B., Albores, J., Wang, T. et al. A Plasmapheresis Protocol for Refractory Pulmonary Alveolar Proteinosis. Lung 193, 209–211 (2015). https://doi.org/10.1007/s00408-014-9678-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-014-9678-2